{"id":1008099,"date":"2026-10-06T08:28:14","date_gmt":"2026-10-06T12:28:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/"},"modified":"2026-10-06T08:28:14","modified_gmt":"2026-10-06T12:28:14","slug":"new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/","title":{"rendered":"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists"},"content":{"rendered":"

<\/p>\n

New Signatera\u2122<\/b>Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists<\/b><\/p>\n

Four oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera<\/i>\u2019<\/i>s role in informing personalized care management, including radiotherapy treatments<\/i><\/p>\n

AUSTIN, Texas–(BUSINESS WIRE<\/a>)–Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Natera\u2019s first participation at ASTRO and a significant step in demonstrating Signatera\u2019s role in treatment response monitoring and risk stratification. All four abstracts were selected for oral presentations, reflecting the breadth of tumor types and treatment settings in which Signatera is demonstrating clinical utility.<\/p>\n

\nTwo presentations from Memorial Sloan Kettering Cancer Center evaluated Signatera for risk stratification in cancers where organ preservation is a treatment goal. In locally advanced rectal cancer (LARC), a real-world study showed that Signatera identified every instance of local cancer growth or recurrence (100% sensitivity), and showed 97% specificity following neoadjuvant treatment. A study in anal squamous cell carcinoma (ASCC) demonstrated that Signatera positivity after definitive chemoradiation therapy (CRT) identified a high-risk group, with 18-month progression-free survival (PFS) of 8% and 18-month overall survival (OS) of 73% after a positive result; among patients who remained Signatera-negative after CRT, 18-month PFS was 97%.<\/p>\n

\nTwo presentations in gynecological cancers further support the value of Signatera as a tool for risk stratification and post-treatment monitoring. The first study found that Signatera status by the end of treatment identified patients with significantly improved progression-free survival in patients with vulvovaginal cancer. Signatera positivity also preceded radiographic recurrence in all patients (100% sensitivity) with a median lead time of 117 days. In the second study, in patients with locally advanced cervical cancer treated with chemoradiation, Signatera positivity at the midpoint of treatment identified a patient with subsequent recurrence nine months later, while all patients who were Signatera-negative at the midpoint remained disease free.<\/p>\n

\n\u201cCancer management is a multidisciplinary effort that includes both local and systemic treatment,\u201d said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection, Natera. \u201cRadiation oncologists are on the front lines of some of the most consequential treatment decisions in cancer care, and the data presented at ASTRO support the value of including Signatera monitoring as part of the clinical toolkit. What excites us about these findings is not just the strength of the data, but what they signal about where this field is heading. We are proud to be generating the evidence to help move it there.\u201d<\/p>\n

Full list of presentations at ASTRO 2026 included:<\/b><\/p>\n

Abstract #1040
\n
<\/b>Presenter: Revathi Ravella, M.D.
\n
Tumor-Informed Circulating Tumor DNA for Prediction of Organ Preservation and Enhanced Surveillance in Locally Advanced Rectal Cancer: A Real-World Cohort<\/i><\/p>\n

Abstract #211
\n
<\/b>Presenter: Bin Gui, M.D., MS
\n
The Prognostic Role of Circulating Tumor DNA in Vulvovaginal Cancers Undergoing Radiotherapy<\/i><\/p>\n

Abstract #213
\n
<\/b>Presenter: Bin Gui, M.D., MS
\n
Circulating Tumor DNA (ctDNA) as an Early Predictive Biomarker of Response in Locally Advanced Cervical Cancer Treated with the Interlace Regimen: A Preliminary Report<\/i><\/p>\n

Abstract #228
\n
<\/b>Presenter: Elisa Liu, M.D.
\n
Circulating Tumor DNA Positivity after Chemoradiation Marks an Imminent High-Risk State in Anal Squamous Cell Carcinoma<\/i><\/p>\n

About Natera
\n
<\/b>Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com<\/a>.<\/p>\n

Forward-Looking Statements
\n
<\/b>All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in \u201cRisk Factors\u201d in Natera\u2019s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com\/investors<\/a> and www.sec.gov<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261006758428\/en\/<\/a><\/span><\/p>\n

\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
\n<\/a>
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Medical Devices Genetics Clinical Trials Biotechnology Radiology Health Science Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists Four oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera\u2019s role in informing personalized care management, including radiotherapy treatments AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Natera\u2019s first participation at ASTRO and a significant step in demonstrating Signatera\u2019s role in treatment response monitoring and risk stratification. All four abstracts were selected for oral presentations, reflecting the breadth of tumor types and treatment settings in which Signatera is demonstrating clinical utility. Two presentations from Memorial Sloan Kettering Cancer Center evaluated Signatera for … <\/p>\n

Continue reading “New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1008099","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNew Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists Four oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera\u2019s role in informing personalized care management, including radiotherapy treatments AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Natera\u2019s first participation at ASTRO and a significant step in demonstrating Signatera\u2019s role in treatment response monitoring and risk stratification. All four abstracts were selected for oral presentations, reflecting the breadth of tumor types and treatment settings in which Signatera is demonstrating clinical utility. Two presentations from Memorial Sloan Kettering Cancer Center evaluated Signatera for … Continue reading "New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-06T12:28:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists\",\"datePublished\":\"2026-10-06T12:28:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/\"},\"wordCount\":889,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/\",\"name\":\"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-10-06T12:28:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/","og_locale":"en_US","og_type":"article","og_title":"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists - Market Newsdesk","og_description":"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists Four oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera\u2019s role in informing personalized care management, including radiotherapy treatments AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Natera\u2019s first participation at ASTRO and a significant step in demonstrating Signatera\u2019s role in treatment response monitoring and risk stratification. All four abstracts were selected for oral presentations, reflecting the breadth of tumor types and treatment settings in which Signatera is demonstrating clinical utility. Two presentations from Memorial Sloan Kettering Cancer Center evaluated Signatera for … Continue reading \"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-06T12:28:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists","datePublished":"2026-10-06T12:28:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/"},"wordCount":889,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/","name":"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-10-06T12:28:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261006758428r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-signateradata-presented-at-astro-conference-highlights-utility-for-radiation-oncologists\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"New Signatera\u2122Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1008099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1008099"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1008099\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1008099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1008099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1008099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}